Dr Reddys Laboratories (RDY) Other Non-Current Assets (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Other Non-Current Assets of $13.0 million for Q1 2026, up 8.33% year-on-year from $12.0 million in Q1 2025, and up 8.33% on a QoQ basis from $12.0 million in Q1 2025.
Dr Reddys Laboratories (RDY) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories (RDY) has reported Other Non-Current Assets for 10 consecutive years, with $13.0 million the latest figure, recorded in Q1 2026.
- Quarterly Other Non-Current Assets rose 8.33% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (up 8.33% YoY) and the FY2026 annual result came in at $13.0 million, up 8.33% from the prior year.
- Other Non-Current Assets rose to $13.0 million in Q1 2026 per RDY's latest filing, from $12.0 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for RDY reached as high as $20.0 million in Q1 2024 and fell as low as $10.0 million in Q1 2023.
- A 5-year average of $13.4 million and a median of $12.0 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets soared 100.0% — and 2025, when it tumbled 40.0%.
- Year by year, Other Non-Current Assets stood at $12.0 million in 2022, then slipped by 16.67% to $10.0 million in 2023, then surged by 100.0% to $20.0 million in 2024, then slumped by 40.0% to $12.0 million in 2025, then rose by 8.33% to $13.0 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $13.0 million, $12.0 million, and $20.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Dr Reddys Laboratories | 9.82 Bn | 9.66 Bn | - | 13.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.00 Mn |
| Mar 31, 2025 | 12.00 Mn |
| Mar 31, 2024 | 20.00 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Mar 31, 2022 | 12.00 Mn |
| Mar 31, 2021 | 11.00 Mn |
| Mar 31, 2020 | 11.00 Mn |
| Mar 31, 2019 | 14.00 Mn |
| Mar 31, 2018 | 16.00 Mn |
| Dec 31, 2009 | 4.00 Mn |
| Sep 30, 2009 | 4.00 Mn |
| Jun 30, 2009 | 4.00 Mn |